Background: Background:HIV-induced activation/inflammation is associated with HIV persistence/reactivation, and is a predictor of morbidity in HIV-infected individuals. HIV-induced activation of myeloid cells promotes trafficking of infected cells to the CNS, and is associated with HIV-induced neurocognitive impairments and HIV-associated dementia. Jak-STAT pathway and tyrosine kinases are activated in macrophages and lymphocytes upon HIV-1 infection, representing attractive cellular targets. As ruxolitinib and baracitinib are Jak1/2 inhibitors either FDA approved or in late phase 3 clinical investigation for myelofibrosis or arthritis respectively, and dasatinib is FDA approved for myeloid malignancies, we evaluated their ability to block 1)HIV replication in primary human macrophages, 2)HIV-induced activation in primary human monocytes and macrophages, and 3)reactivation of latent HIV in T cells.
Methods: Methods: Macrophages were treated with various concentrations of ruxolitinib, baracitinib, or dasatinib for 2hr prior to infection (HIV-1baL). Cells were maintained for 6 days before viral quantification (p24-ELISA). Macrophages or monocytes were treated with various concentrations of drug prior to infection (HIV-1baL), and maintained for 3 or 6 days before quantification of HLA-DR, CD163, CCR5 (macrophages), or CD14/CD16 (monocytes). Macrophages and monocytes were treated with various concentrations of drug for 6 days and stained with Near-IR live/dead dye and quantified by FACS. J-lat latent T cells were treated with various concentrations of drug plus TNF-a and reactivation was quantified by GFP reporter 24 hr post induction.
Results: Results: Ruxolitinib, baracitinib, and dasatinib were not cytotoxic (>50 µM for ruxolitinib/baracitinib; 20µM) and demonstrated 1)antiviral potency ranging from 0.001-0.08µM in macrophages, 2)inhibition of HIV-induced upregulation of CCR5, CD163, and HLA-DR (macrophages) and CD14/CD16 (monocytes), and inhibition of reactivation of latent HIV-1 in T cells (p<0.05 versus no drug controls).
Conclusions: Conclusions:Ruxolitinib, baracitinib, and dasatinib inhibit HIV replication in macrophages, reactivation of latent HIV-1 (T-cells), and HIV-induced activation markers (monocytes/macrophages), which are linked to trafficking of infected cells to the CNS, disease progression, and neurocognitive dysfunction. Selectively blocking Jak-STAT or tyrosine kinase signaling could reverse or prevent HIV-mediated immune activation both systemically and within the brain/CNS.